anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Inflammation has been reported to increase zonulin levels, a protein that regulates intestinal permeability. The aim of this study was to investigate the association of serum zonulin levels with preterm labor in pregnant women.
PATIENTS AND METHODS: A total of 180 pregnant women between 32-42 weeks of gestation were included in the study. Among those whose gestational week is less than 37, preterm labor (group 1), normal course pregnant (group 2), and gestational weeks between 37-42 pregnant women with normal course (group 3), term labor (group 4) groups were formed.
RESULTS: Zonulin levels were not statistically different between groups. Among the inflammation markers, only C-reactive protein levels were significantly higher in group 1 compared to groups 2 and 3. There were a total of 18/90 (20%) pregnant women with premature rupture of membranes (PROM) in the delivery groups. The mean zonulin level was higher in those with PROM (155.3±50.2 ng/ml) than those without PROM (128.8±59 ng/ml). However, there was no statistically significant difference between them.
CONCLUSIONS: In conclusion, serum zonulin levels were not useful as a marker for predicting preterm labor. However, examining large-scale studies about the relationship between PROM and zonulin is still needed.
<P>PROBLEM TO BE SOLVED: To provide an image processor and an image processing method searching an affected portion from all images based on diagnosis information and selecting an image or an image set including the lesion portion.  <P>SOLUTION: In a step S1, imaging data are input in an image input part 1. In a step S2, diagnosis results using the imaging data by a doctor are input in a diagnosis information input part 2 as diagnosis information. In a step S3, key words input in the diagnosis information input part 2 or a diagnosis information analysis part 3 are searched from a keyword table 7. In a step S4, a parameter determination part 5 selects initial value parameters to be used in an image search part 4 are selected from the initial value table 8 based on the input keywords. In steps S5 and S6, the image search part 4 determines the appropriateness of the parameters based on the area and the connectivity of the lesion area by applying the selected parameters to the input image and extracts the lesion area using a general computer diagnosis supporting technology.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
<P>PROBLEM TO BE SOLVED: To provide a composition for oral administration containing itraconazole.  <P>SOLUTION: The composition for the oral administration contains 1 pt. wt. itraconazole, 0.1-0.5 pt. wt. citric acid and 0.1-0.5 pt. wt. hydroxypropyl methyl cellulose. The composition obviates the inconvenience possessed by a conventional preparation by reducing an amount of a used additive used for solubilizing the itraconazole, and can reduce a production cost by decreasing the time for a spray drying process. The composition exhibits a high solubility and leaching rate, and has excellent repeatability and preservation stability.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
An intake to exit security system for high-volume pharmacies provides maximum security from tampering and assures accuracy. The system immediately assigns bar codes to shipments upon arrival and then tracks them through warehousing, bulk distribution, prescription dispensing and shipping to patients, hospitals and drugstores. Bar-coded lock neck devices secure bulk drug canisters to bar-coded dispensing machines at specified dispensing stations where the machines dispense drugs into pre-labeled prescription bottles according to prescription indicia on the labels. Bottles then undergo content analysis and certification before being packaged and shipped to customers. A Ramon laser spectral analysis contrasts the bottle contents to a library of known spectral signatures of drugs, and the pharmacist is alerted to any detected difference. A simultaneously captured visual image of the pills enables the pharmacist visually to compare the contents to a library of known visual appearances of the drugs. Both analyses are recorded for prescriptions certified and forwarded to customers. Deviations are excised without disrupting flow of other prescriptions, and the system automatically reassigns an incorrectly filled prescription to another bottle which starts anew through the system. Full bottles of commonly used drugs and specialized containers for irregularly shaped objects, creams and ointments may be pre-filled and inventoried for later collation with prescription bottles at the packaging and shipping stage.
PURPOSE: Single chain antibody molecules provided. And also, nucleic acids coding for the molecules, a vector comprising them and their uses are provided. The single chain antibody directed against p53 protein is expressed in a tumoral cell, restores a DNA binding in vitro and transcription activator function in vivo. CONSTITUTION: A method for restoring p53-dependent transcription activator function in tumor cells having a mutant p53 protein is characterized by comprising the introduction of single chain antibodies binding specifically to the mutant p53 protein, to tumoral cells. Nucleic acids comprising a sequence coding the single chain antibodies are introduced to the cell by using a viral, chemical or plasmid vector under the control of a promotor functioning in the cells. The single chain antibodies are used for a treatment of hyperpropagation disease caused by mutant p53 protein, in particular epitope, which is located at between 320-393 of p53 C-end region and transports oligomerized domain and regulation domain.
Regarding CG, the participants were invited to the same room and received only a single time attention-matched education on "Living with MS"; including definition of MS, dietary advices for MS patients. The attention-matched education was performed face to face and lasted for 10 min. All participants in the three study groups also received usual treatment and care.
Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
The overall incidence of postoperative vomiting between 25 and 30% for the pediatric population, but it can reach a much higher incidence associated with certain types of surgery, about 80% in some studies like strabismus surgery for example. The identification of patients at high risk of POV is possible through the use of risk score. It is currently only one pediatric validated risk score, but the investigators conducted a multicenter study on this subject, whose results are being analyzed. This should allow us to identify children at high risk of POV. In this targeted population, the prophylaxis should allow a significant reduction in the incidence of POV. In children only one study tried to evaluate the association of ondansetron, dexamethasone and droperidol to prevent postoperative vomiting. However, different doses of the different molecules were combined, the extremely complicated design of this study and important methodological bias do not provide evidence about the superiority of the combination of three anti-emetics compared with two anti-emetics. Our present randomized, double-blind study is designed to compare the effectiveness of Droperidol in combination with a conventional bi-prophylaxis (dexamethasone/ondansetron) to the conventional bi-prophylaxis alone to decrease the occurrence of postoperative vomiting in children at high risk. The combination ondansetron and dexamethasone is frequently assessed as an association to prevent postoperative vomiting also in the adult population and in the pediatric population.
Due to its physiological benefits from in vitro and in vivo points of view, Akkermansia muciniphila, a common colonizer in the human gut mucous layer, has consistently been identified as an option for the next-generation probiotic. A. muciniphila is a significant bacterium that promotes host physiology. However, it also has a great deal of potential to become a probiotic due to its physiological advantages in a variety of therapeutic circumstances. Therefore, it can be established that the abundance of A. muciniphila in the gut environment, which is controlled by many genetic and dietary variables, is related to the biological behaviors of the intestinal microbiota and gut dysbiosis/eubiosis circumstances. Before A. muciniphila is widely utilized as a next-generation probiotic, regulatory obstacles, the necessity for significant clinical trials, and the sustainability of manufacturing must be eliminated. In this review, the outcomes of recent experimental and clinical reports are comprehensively reviewed, and common colonization patterns, main factors involved in the colonization of A. muciniphila in the gut milieu, their functional mechanisms in establishing homeostasis in the metabolic and energy pathways, the promising delivery role of microencapsulation, potential genetic engineering strategies, and eventually safety issues of A. muciniphila have been discussed.
Participants in this arm will undergo a focused echocardiogram every 24 hours. The degree of diastolic dysfunction will be reported to the healthcare team. If the degree of diastolic dysfunction is greater than or equal to grade 2, the research team will recommend escalating the diuretic regimen if either (1) urine output is less than 4,000 mL over 24 hours or (2) weight loss is less than 2 kg over 24 hours. If the degree of diastolic dysfunction is grade 1, the research team will recommend transitioning to or discontinuing oral diuresis.
ABSTRACT OF THE DISCLOSURE     Infectious bronchitis vaccines for poultry derived from at least one virus strain of a novel serotype of the infectious bronchitis virusses, identified by the internal indications Utrecht.101, Utrecht.102, Drente.201, Limburg.501, Limburg.502, Limburg.503, Brabant.801, Limburg.536, Overijssel.728 and Utrecht.121, which have been deposited with the Czechoslovak National Collection of Type Cultures of the Institute of Hygiene and Epidemiology under the numbers: CNCTC A 07/80, CNCTC A 08/80, CNCTC A 09/80, CNCTC A010/80, CNCTC A 011/80 CNCTC A 012/80, CNCTC A 016/80, CNCTC A 014/80, CNCTC A 015/80 and CNCTC A 013/80; combined infectious bronchitis vaccines, derived from the IBV-H120 or the IBV-H52 of the Massachusetts type strain, in addition to one or more of the beforementioned strains and the infectious bronchitis virus strains themselves; a process for the preventing of infectious bronchitis with poultry by vaccination with the vaccine, derived from the beforementioned strains.  Preferably infectious bronchitis vaccines are derived from the virus strains Utrecht.101, deposited under nr. CNCTC A 07/80, Lim-burg.536, deposited under nr. CNCTC A 014/80 and Overijssel.728, deposited under nr. CNCTC A 015/80; preferably the live infectious bronchitis vaccines are prepared, which are containing a virus content of ? 104.0 EID50 pro dosage of each of the virus strains after freeze drying.
The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). The present document updates the 2018 research framework in response to several recent developments. Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD. The present document is consistent with this principle. Our intent is to present objective criteria for diagnosis and staging AD, incorporating recent advances in biomarkers, to serve as a bridge between research and clinical care. These criteria are not intended to provide step-by-step clinical practice guidelines for clinical workflow or specific treatment protocols, but rather serve as general principles to inform diagnosis and staging of AD that reflect current science. HIGHLIGHTS: We define Alzheimer's disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms. Early-changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway; however, these reflect the presence of ADNPC more generally (i.e., both neuritic plaques and tangles). An abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making throughout the disease continuum. Later-changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms. An integrated biological and clinical staging scheme is described that accommodates the fact that common copathologies, cognitive reserve, and resistance may modify relationships between clinical and biological AD stages.
PURPOSE:To produce a maltitol tablet confectionery having smooth palatability and good flavor and lasting property in the mouth, by adding powdery maltitol to a uniform emulsified solution consisting of a fat or oil, secondary raw material, etc., kneading the resultant mixture while heating, granulating the kneaded mixture and tableting the resultant granule. CONSTITUTION:A fat or oil, emulsifying agent and a solid secondary raw material, e.g. colorant, sour agent, powdery extract or powdery perfume, and a liquid secondary raw material, e.g. perfume or fruit juice, are mixed with water and stirred to prepare a uniform emulsified solution. Powdery maltitol and preferably an aqueous solution of an alcohol are then added to the above- mentioned emulsified solution, and the resultant mixture is kneaded while heating. The resultant paste is granulated while heating to give a granular form and the granules are dried and tableted.
Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease that can manifest itself with a variety of skin symptoms. Periorbital erythema, a rare variant of CLE, presents challenges in terms of diagnosis and treatment. Here, we report a case of CLE presenting with periorbital erythema and edema. A 42-year-old female patient presented with complaints of erythema, edema, and scaling on the right eyelid that started four months ago. A skin biopsy was performed on the lesioned skin of the eyelid to differentiate dermatomyositis, cutaneous lupus erythematosus, sarcoidosis, lupus vulgaris, and cutaneous lymphoma. Histopathological examination revealed focal hyperkeratosis and parakeratosis on the surface of the epidermis, vacuolar degeneration in the basal layer of the epidermis, lymphocyte exocytosis with necrotic keratinocytes, edema in the dermis, melanophages, and perivascular, periadnexal lymphocytic reaction. Laboratory tests showed negative antinuclear antibody and anti-dsDNA, but positivity for anti-Ro-52. In the absence of any other complaints, the patient was diagnosed with cutaneous lupus erythematosus presenting with periorbital erythema based on clinical, histopathological, and laboratory findings. Hydroxychloroquine 200 mg/day, topical corticosteroid, and topical tacrolimus were administered. Two months later, significant improvement in the lesions was observed. In conclusion, it should be kept in mind that periorbital erythema can develop as a rare variant of CLE and can be misdiagnosed as contact dermatitis, dermatomyositis, sarcoidosis, or cutaneous lymphoma. Additionally, the ANA and anti-dsDNA antibodies are often found to be negative in these cases. In establishing the diagnosis, firstly considering the disease, followed by histopathological examinations and laboratory tests, is crucial.
INTRODUCTION: Lower respiratory tract infections (LRTI) remain a significant global cause of mortality and disability. Viruses constitute a substantial proportion of LRTI cases, with their pandemic potential posing a latent threat. After the SARS-CoV-2 pandemic, the resurgence of other respiratory viruses, including Influenza and Respiratory Syncytial Virus responsible for LRTI has been observed especially in susceptible populations.
AREAS COVERED: This review details the inflammatory mechanisms associated with three primary respiratory viruses: SARS-CoV-2, Influenza, and Respiratory Syncytial Virus (RSV). The focus will be on elucidating the activation of inflammatory pathways, understanding cellular contributions to inflammation, exploring the role of interferon and induced cell death in the response to these pathogens and detailing viral evasion mechanisms. Furthermore, the distinctive characteristics of each virus will be explained.
EXPERT OPINION: The study of viral pneumonia, notably concerning SARS-CoV-2, Influenza, and RSV, offers critical insights into infectious and inflammatory mechanisms with wide-ranging implications. Addressing current limitations, such as diagnostic accuracy and understanding host-virus interactions, requires collaborative efforts and investment in technology. Future research holds promise for uncovering novel therapeutic targets, exploring host microbiome roles, and addressing long-term sequelae. Integrating advances in molecular biology and technology will shape the evolving landscape of viral pneumonia research, potentially enhancing global public health outcomes.
FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period.
S1P receptor modulators, including GILENYA, have been associated with an increased risk of macular edema. Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with GILENYA. Perform an examination of the fundus, including the macula, 3 to 4 months after starting treatment, periodically while on therapy, and any time there is a change in vision.

A dose-dependent increase in the risk of macular edema occurred in the GILENYA clinical development program.

In 2-year double-blind, placebo-controlled studies in adult patients with multiple sclerosis, macular edema with or without visual symptoms occurred in 1.5% of patients (11/799) treated with fingolimod 1.25 mg, 0.5% of patients (4/783) treated with GILENYA 0.5 mg, and 0.4% of patients (3/773) treated with placebo. Macular edema occurred predominantly during the first 3 to 4 months of therapy. These clinical trials excluded patients with diabetes mellitus, a known risk factor for macular edema (see below Macular Edema in Patients with History of Uveitis or Diabetes Mellitus). Symptoms of macular edema included blurred vision and decreased visual acuity. Routine ophthalmological examination detected macular edema in some patients with no visual symptoms. Macular edema generally partially or completely resolved with or without treatment after drug discontinuation. Some patients had residual visual acuity loss even after resolution of macular edema. Macular edema has also been reported in patients taking GILENYA in the postmarketing setting, usually within the first 6 months of treatment.

Continuation of GILENYA in patients who develop macular edema has not been evaluated. Macular edema over an extended period of time (i.e., 6 months) can lead to permanent visual loss. Consider discontinuing GILENYA if macular edema develops; this decision should include an assessment of the potential benefits and risks for the individual patient. The risk of recurrence after rechallenge has not been evaluated.

Macular Edema in Patients with History of Uveitis or Diabetes Mellitus

Patients with a history of uveitis and patients with diabetes mellitus are at increased risk of macular edema during GILENYA therapy. In the combined clinical trial experience in adult patients with all doses of fingolimod, the rate of macular edema was higher in MS patients with a history of uveitis compared to those without a history of uveitis (approximately 20% versus 0.6%, respectively). GILENYA has not been tested in MS patients with diabetes mellitus.
Placebo administration: Orally 750 ml per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 750 ml per day in 3 doses (250 ml each).